Skip to main content

Alaunos Therapeutics, Inc.

TCRT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001107421

No open-market purchases or sales by Alaunos Therapeutics, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $204.4K in total; no superinvestor holds it.

Q4 2025 vs. Q3 2025

How the institutions holding Alaunos Therapeutics, Inc. changed between Q3 2025 and Q4 2025.

All holders in Q4 2025All holders in Q3 2025

13F holders of TCRT: Q3 2025 compared with Q4 2025
MeasureQ3 2025Q4 2025Change
Holders2627+1
Shares65.4K108.5K+43.1K (+65.9%)
Value$158.3K$349.9K+$191.6K (+121.0%)

New holders (6)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q4 2025 but not at the end of Q3 2025.

Institutions new to TCRT in Q4 2025
InstitutionSharesValue% of portfolio
Two Sigma Investments, LP18,588$60.0K0.00%
HRT Financial LP12,602$40.0K0.00%
Citigroup Inc89$2870.00%
CWM Advisors, LLC10$340.00%
Tidemark, LLC2$60.00%
Tucker Asset Management LLC1$30.00%

Sold out (5)

Institutions that held Alaunos Therapeutics, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.

Institutions that sold out of TCRT in Q4 2025
InstitutionShares, Q3 2025Value, Q3 2025
Barclays PLC50$121
Asset Dedication, LLC46$111
Wealthspire Advisors, LLC1$3
Truvestments Capital LLC1$2
Royal Bank of Canada198$0